PSMA-targeted imaging and theragnostics have redefined the diagnostic and therapeutic landscape of prostate cancer, enabling earlier detection, improved risk stratification, and biologically guided treatment across all disease stages. This evidence concerns the gene FOLH1 and prostate carcinoma.